Personalized medicine in diabetes: The role of 'omics' and biomarkers

Diabetic Medicine

Volumn 33, Issue 6, 2016, Pages 712-717

  Pearson, E R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL MARKER; C PEPTIDE; CYTOCHROME P450 2C9; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; METFORMIN; ORGANIC CATION TRANSPORTER 1; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; CYP2C9 PROTEIN, HUMAN; INSULIN;

DIABETES MELLITUS; DRUG CHOICE; DRUG DISPOSITION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SENSITIVITY; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; INSULIN DEFICIENCY; INSULIN RESISTANCE; METABOLOMICS; METAGENOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DEFICIENCY; GENETICS; GENOMICS; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; PROCEDURES;

BIOMARKERS; CYTOCHROME P-450 CYP2C9; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METABOLOMICS; ORGANIC CATION TRANSPORTER 1; PRECISION MEDICINE;

EID: 84968784374     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13075     Document Type: Review

References (28)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
2. Arar NH, Freedman BI, Adler SG, Iyengar SK, Chew EY, Davis MD et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci 2008; 49: 3839-3845.
3. Zhou K, Donnelly L, Yang J, Li M, Deshmukh H, Van Zuydam N et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2014; 2: 481-487.
4. Jones AG, McDonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA et al. Markers of beta-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care 2016; 39: 250-257.
5. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-170.
6. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362: 1275-1281.
7. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 2003; 26: 3191-3192.
8. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010; 53: 2504-2508.
9. Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G et al. Loss-of-Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go-DARTS Study. Clin Pharmacol Ther 2010; 87: 52-56.
10. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009; 10: 1781-1787.
11. Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol 2011; 67: 471-476.
12. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431.
13. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER. Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes 2015; 64: 1786-1793.
14. Dujic T, Causevic A, Bego T, Malenica M, Velija-Asimi Z, Pearson ER et al. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabet Med 2016; 33: 511-514.
15. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K, Bellenguez C, Spencer CC, Bennett AJ et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genet 2011; 43: 117-120.
16. Van Leeuwen N, Nijpels G, Becker ML, Deshmukh H, Zhou K, Stricker BH et al. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia 2012; 55: 1971-1977.
17. Zhou Y, Guo Y, Ye W, Wang Y, Li X, Tian Y et al. RS11212617 is associated with metformin treatment response in type 2 diabetes in Shanghai local Chinese population. Int J Clin Pract 2014; 68: 1462-1466.
18. Mavrou A, Tsangaris GT, Roma E, Kolialexi A. The ATM gene and ataxia telangiectasia. Anticancer Res 2008; 28: 401-405.
19. Schalch DS, McFarlin DE, Barlow MH. An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med 1970; 282: 1396-1402.
20. Connelly PJ, Smith N, Chadwick R, Exley AR, Shneerson JM, Pearson ER. Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance. Diabet Med 2016; 33: 371-375.
21. Li H, Jia W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther 2013; 94: 574-581.
22. Kaddurah-Daouk R, Weinshilboum R. Pharmacometabolomics Research Network. Metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine. Clin Pharmacol Ther 2015; 98: 71-75.
23. Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry 2011; 1. pii: e26.
24. Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983; 220: 325-327.
25. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981; 305: 789-794.
26. McCreight L, Bailey CJ, Pearson ER. Metformin and the gut. Diabetologia 2016; 59: 426-435.
27. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528: 262-266.
28. Burton JH, Johnson M, Johnson J, Hsia DS, Greenway FL, Heiman ML. Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels. J Diabetes Sci Technol 2015; 9: 808-814.